Muscle channelopathies.

ABSTRACT PURPOSE OF REVIEW This article describes the clinical features, diagnosis, pathophysiology, and management of nondystrophic myotonia and periodic paralysis. RECENT FINDINGS An increasing awareness exists about the genotype-phenotype overlap in skeletal muscle channelopathies, and thus genetic testing is needed to make a definitive diagnosis. Electrodiagnostic testing in channelopathies is highly specialized with significant overlap in various mutation subtypes. Randomized clinical trials have now been conducted in these disorders with expanded treatment options for patients with muscle channelopathies. SUMMARY Skeletal muscle channelopathies are rare heterogeneous conditions characterized by lifelong symptoms that require a comprehensive management plan that includes pharmacologic and nonpharmacologic interventions. The significant variability in biophysical features of various mutations, coupled with the difficulties of performing clinical trials in rare diseases, makes it challenging to design and implement treatment trials for muscle channelopathies.

[1]  V. Sansone.  The Dystrophic and Nondystrophic Myotonias , 2016, Continuum.

[2]  A. De Luca,et al.  Therapeutic Approaches to Genetic Ion Channelopathies and Perspectives in Drug Discovery , 2016, Front. Pharmacol..

[3]  G. Meola,et al.  SCN4A mutation as modifying factor of Myotonic Dystrophy Type 2 phenotype , 2015, Neuromuscular Disorders.

[4]  S. Cannon.  Channelopathies of skeletal muscle excitability. , 2015, Comprehensive Physiology.

[5]  R. Ruff,et al.  Disorders of Skeletal Muscle Membrane Excitability: Myotonia Congenita, Paramyotonia Congenita, Periodic Paralysis, and Related Syndromes , 2014 .

[6]  M. Hanna,et al.  Mutations in SCN4A: A Rare but Treatable Cause of Recurrent Life-Threatening Laryngospasm , 2014, Pediatrics.

[7]  A. Wilde,et al.  Cardiac arrhythmias in hypokalemic periodic paralysis: Hypokalemia as only cause? , 2014, Muscle & nerve.

[8]  J. Trivedi,et al.  Treatment and Management of Neuromuscular Channelopathies , 2014, Current Treatment Options in Neurology.

[9]  J. Statland,et al.  Muscle Channelopathies: the Nondystrophic Myotonias and Periodic Paralyses , 2013, Continuum.

[10]  T. Yousry,et al.  Muscle MRI reveals distinct abnormalities in genetically proven non-dystrophic myotonias☆ , 2013, Neuromuscular Disorders.

[11]  S. Cannon,et al.  Non-dystrophic myotonia: prospective study of objective and patient reported outcomes. , 2013, Brain : a journal of neurology.

[12]  M. Kornhuber,et al.  Diagnostic impact of myotonic discharges in myofibrillar myopathies , 2013, Muscle & nerve.

[13]  M. Hanna,et al.  Prevalence study of genetically defined skeletal muscle channelopathies in England , 2013, Neurology.

[14]  S. Cannon,et al.  A calcium channel mutant mouse model of hypokalemic periodic paralysis. , 2012, The Journal of clinical investigation.

[15]  J. Desaphy,et al.  Dramatic improvement of myotonia permanens with flecainide: a two-case report of a possible bench-to-bedside pharmacogenetics strategy , 2012, European Journal of Clinical Pharmacology.

[16]  R. Griggs,et al.  Mexiletine for symptoms and signs of myotonia in nondystrophic myotonia: a randomized controlled trial. , 2012, JAMA.

[17]  S. Pandya,et al.  Role of disease severity, illness perceptions, and mood on quality of life in muscle disease , 2012, Muscle & nerve.

[18]  G. Apolone,et al.  Measuring quality of life impairment in skeletal muscle channelopathies , 2012, European journal of neurology.

[19]  F. Thyssen,et al.  Myotonia congenita and myotonic dystrophy in the same family: coexistence of a CLCN1 mutation and expansion in the CNBP (ZNF9) gene , 2011, Clinical genetics.

[20]  R. Griggs,et al.  Acetazolamide efficacy in hypokalemic periodic paralysis and the predictive role of genotype , 2011, Neurology.

[21]  S. Cannon,et al.  A sodium channel knockin mutant (NaV1.4-R669H) mouse model of hypokalemic periodic paralysis. , 2011, The Journal of clinical investigation.

[22]  M. Koltzenburg,et al.  Refined exercise testing can aid dna‐based diagnosis in muscle channelopathies , 2011, Annals of neurology.

[23]  M. Hanna,et al.  Skeletal muscle channelopathies: nondystrophic myotonias and periodic paralysis. , 2010, Current opinion in neurology.

[24]  G. Lesca,et al.  Severe neonatal episodic laryngospasm due to de novo SCN4A mutations , 2010, Neurology.

[25]  S. Cannon.  Voltage‐sensor mutations in channelopathies of skeletal muscle , 2010, The Journal of physiology.

[26]  M. Hanna,et al.  Muscle channelopathies: does the predicted channel gating pore offer new treatment insights for hypokalaemic periodic paralysis? , 2010, The Journal of physiology.

[27]  L. Ptáček,et al.  Mutations in Potassium Channel Kir2.6 Cause Susceptibility to Thyrotoxic Hypokalemic Periodic Paralysis , 2010, Cell.

[28]  G. Holmgren,et al.  Spectrum of CLCN1 mutations in patients with myotonia congenita in Northern Scandinavia , 2001, European Journal of Human Genetics.

[29]  S. Cannon,et al.  The non-dystrophic myotonias: molecular pathogenesis, diagnosis and treatment. , 2010, Brain : a journal of neurology.

[30]  D. Kullmann,et al.  Voltage sensor charge loss accounts for most cases of hypokalemic periodic paralysis , 2009, Neurology.

[31]  G. Drost,et al.  Redefining the clinical phenotypes of non-dystrophic myotonic syndromes , 2009, Journal of Neurology, Neurosurgery, and Psychiatry.

[32]  Hanns Lochmüller,et al.  High frequency of co-segregating CLCN1 mutations among myotonic dystrophy type 2 patients from Finland and Germany , 2008, Journal of Neurology.

[33]  T. Miller.  Differential diagnosis of myotonic disorders , 2008, Muscle & nerve.

[34]  M. Davis,et al.  What causes paramyotonia in the United Kingdom? , 2008, Neurology.

[35]  D. Saperstein,et al.  Muscle Channelopathies , 2006, Seminars in neurology.

[36]  Bertrand Fontaine.  Periodic paralysis. , 2008, Advances in genetics.

[37]  D. Kullmann,et al.  Chloride channel myotonia: exon 8 hot-spot for dominant-negative interactions. , 2007, Brain : a journal of neurology.

[38]  J. Willer,et al.  Cold extends electromyography distinction between ion channel mutations causing myotonia , 2006, Annals of neurology.

[39]  S. Cannon.  Pathomechanisms in channelopathies of skeletal muscle and brain. , 2006, Annual review of neuroscience.

[40]  D. Camerino,et al.  Carbonic anhydrase inhibitors ameliorate the symptoms of hypokalaemic periodic paralysis in rats by opening the muscular Ca2+-activated-K+channels , 2006, Neuromuscular Disorders.

[41]  S. Cannon,et al.  The primary periodic paralyses: diagnosis, pathogenesis and treatment. , 2006, Brain : a journal of neurology.

[42]  E. Colding-Jørgensen.  Phenotypic variability in myotonia congenita , 2005, Muscle & nerve.

[43]  R. Cantello,et al.  Myotonia congenita and myotonic dystrophy: Descriptive epidemiological investigation in Turin, Italy (1955–1979) , 1982, The Italian Journal of Neurological Sciences.

[44]  Timothy A. Miller,et al.  Correlating phenotype and genotype in the periodic paralyses , 2004, Neurology.

[45]  J. Willer,et al.  Electromyography guides toward subgroups of mutations in muscle channelopathies , 2004, Annals of neurology.

[46]  J. Weissenbach,et al.  Genetic heterogeneity in hypokalemic periodic paralysis (hypoPP) , 1994, Human Genetics.

[47]  E. Hoffman,et al.  Novel CLCN1 mutations with unique clinical and electrophysiological consequences. , 2002, Brain : a journal of neurology.

[48]  P. Chinnery,et al.  Normokalemic periodic paralysis revisited: Does it exist? , 2002, Annals of neurology.

[49]  Hubert Kwiecinski,et al.  Functional and clinical characterization of KCNJ2 mutations associated with LQT7 (Andersen syndrome). , 2002, The Journal of clinical investigation.

[50]  Y. Rajabally,et al.  Hypokalemic periodic paralysis associated with malignant hyperthermia , 2002, Muscle & nerve.

[51]  J. Gilchrist.  Muscle disease. , 2002, Advances in neurology.

[52]  F. Lehmann-Horn,et al.  Periodic paralysis: Understanding channelopathies , 2002, Current neurology and neuroscience reports.

[53]  R. Griggs,et al.  Sodium channel inactivation defects are associated with acetazolamide‐exacerbated hypokalemic periodic paralysis , 2001, Annals of neurology.

[54]  F. Lehmann-Horn,et al.  Hypokalaemic periodic paralysis type 2 caused by mutations at codon 672 in the muscle sodium channel gene SCN4A. , 2001, Brain : a journal of neurology.

[55]  S. Subramony,et al.  Mutations in Kir2.1 Cause the Developmental and Episodic Electrical Phenotypes of Andersen's Syndrome , 2001, Cell.

[56]  G. Holmgren,et al.  Spectrum of CLCN1 mutations in patients with myotonia congenita in Northern Scandinavia , 2001, European Journal of Human Genetics.

[57]  S. Orcesi,et al.  Response to carbamazepine of recessive‐type myotonia congenita , 2000, Muscle & nerve.

[58]  R. Orrell,et al.  Familial cramp due to potassium-aggravated myotonia , 1998, Journal of neurology, neurosurgery, and psychiatry.

[59]  N. Wood,et al.  Salbutamol treatment in a patient with hyperkalaemic periodic paralysis due to a mutation in the skeletal muscle sodium channel gene (SCN4A) , 1998, Journal of neurology, neurosurgery, and psychiatry.

[60]  V. Myllylä,et al.  Myotonia congenita in northern Finland: an epidemiological and genetic study. , 1998, Journal of medical genetics.

[61]  R. Griggs,et al.  Andersen's syndrome: A distinct periodic paralysis , 1997, Annals of neurology.

[62]  F. Lehmann-Horn,et al.  Channelopathies: the nondystrophic myotonias and periodic paralyses. , 1996, Seminars in pediatric neurology.

[63]  M. Koch,et al.  Mutations in dominant human myotonia congenita drastically alter the voltage dependence of the CIC-1 chloride channel , 1995, Neuron.

[64]  R. Moxley,et al.  Myotonia fluctuans. A third type of muscle sodium channel disease. , 1994, Archives of neurology.

[65]  Rabi Tawil,et al.  Andersen's syndrome: Potassium‐sensitive periodic paralysis, ventricular ectopy, and dysmorphic features , 1994, Annals of neurology.

[66]  B. Fontaine.  Periodic paralysis, myotonia congenita and sarcolemmal ion channels: A success of the candidate gene approach , 1993, Neuromuscular Disorders.

[67]  E. Hoffman,et al.  Duchenne-Becker muscular dystrophy and the nondystrophic myotonias. Paradigms for loss of function and change of function of gene products. , 1993, Archives of neurology.

[68]  R. Griggs,et al.  Acetazolamide‐induced nephrolithiasis , 1993, Neurology.

[69]  R. Griggs,et al.  Genetics and physiology of the myotonic muscle disorders. , 1993, The New England journal of medicine.

[70]  M. Leppert,et al.  Mutations in an S4 segment of the adult skeletal muscle sodium channel cause paramyotonia congenita , 1992, Neuron.

[71]  A. Emery.  Population frequencies of inherited neuromuscular diseases—A world survey , 1991, Neuromuscular Disorders.

[72]  G. Lathrop,et al.  Paramyotonia congenita and hyperkalemic periodic paralysis are linked to the adult muscle sodium channel gene , 1991, Annals of neurology.

[73]  Margaret Robertson,et al.  Identification of a mutation in the gene causing hyperkalemic periodic paralysis , 1991, Cell.

[74]  M. Leppert,et al.  Paramyotonia congenita and hyperkalemic periodic paralysis map to the same sodium-channel gene locus. , 1991, American journal of human genetics.

[75]  M. Leppert,et al.  Analysis in a large hyperkalemic periodic paralysis pedigree supports tight linkage to a sodium channel locus. , 1991, American journal of human genetics.

[76]  M. Zwarts,et al.  Permanent muscle weakness in familial hypokalaemic periodic paralysis. Clinical, radiological and pathological aspects. , 1990, Brain : a journal of neurology.

[77]  J. Haines,et al.  Hyperkalemic periodic paralysis and the adult muscle sodium channel alpha-subunit gene. , 1990, Science.

[78]  R. Griggs,et al.  Acetazolamide‐responsive myotonia congenita , 1987, Neurology.

[79]  E. Streib.  Paramyotonia congenita: Successful treatment with tocainide. Clinical and electrophysiologic findings in seven patients , 1987, Muscle & nerve.

[80]  J. Daube,et al.  The exercise test in periodic paralysis , 1986, Muscle & nerve.

[81]  A. Heller,et al.  Efficacy of phenytoin, procainamide, and tocainide in murine genetic myotonia , 1985, Experimental Neurology.

[82]  W. Engel,et al.  Intravenous treatment of hypokalemic periodic paralysis. , 1983, Archives of neurology.

[83]  W. Engel,et al.  Treatment of “permanent” muscle weakness in familial hypokalemic periodic paralysis , 1983, Muscle & nerve.

[84]  H. Lorković,et al.  Two cases of adynamia episodica hereditaria: In vitro investigation of muscle cell membrane and contraction parameters , 1983, Muscle & nerve.

[85]  R. Griggs,et al.  Hypokalemic periodic paralysis exacerbated by acetazolamide , 1981, Neurology.

[86]  H. Lorković,et al.  Membrane defects in paramyotonia congenita with and without myotonia in a warm environment , 1981, Muscle & nerve.

[87]  D. Bates,et al.  Hypothyroidism with true myotonia. , 1978, Journal of neurology, neurosurgery, and psychiatry.

[88]  P. Lichter,et al.  Patient tolerance to carbonic anhydrase inhibitors. , 1978, American journal of ophthalmology.

[89]  R. Griggs,et al.  Cardiac conduction in myotonic dystrophy. , 1975, The American journal of medicine.

[90]  R. H. Adrian,et al.  On the repetitive discharge in myotonic muscle fibres , 1974, The Journal of physiology.

[91]  S H Bryant,et al.  Chloride conductance in normal and myotonic muscle fibres and the action of monocarboxylic aromatic acids , 1971, The Journal of physiology.

[92]  W. Engel,et al.  Acetazolamide treatment of hypokalemic periodic paralysis. Prevention of attacks and improvement of persistent weakness. , 1970, Annals of internal medicine.

[93]  Y. Shishiba.  [Treatment of periodic paralysis]. , 1970, Naika. Internal medicine.

[94]  J. Walton,et al.  The treatment of myotonia: a controlled clinical trial. , 1959, Brain : a journal of neurology.

[95]  Jacqueline Palace,et al.  Atypical periodic paralysis and myalgia , 2018, Neurology.